The continued plague of active smoking at the time of interventions for intermittent claudication

Evaluating the management of intermittent claudication before and after publication of the Society of Vascular Surgery's Appropriate Use Criteria

OBJECTIVE

In April 2022, the Society for Vascular Surgery (SVS) published the Appropriate Use Criteria (AUC) for the management of intermittent claudication (IC). Our goal was to compare practice patterns before and after publication of the AUC to identify changes.

METHODS

The Vascular Quality Initiative (VQI) peripheral vascular intervention (PVI) and suprainguinal and infrainguinal bypass registries were analyzed for interventions for IC. Relevant patient and intervention characteristics pre-AUC (2018-2019) and post-AUC (May 2022-December 2023) were compared. Key points of the AUC that are analyzable from the VQI include claudication severity, use of optimal medical therapy (OMT), smoking status, high-risk comorbid conditions (as indicators of operative risk), operative management of complex aortoiliac and femoropopliteal disease (TASC II C/D), common femoral artery (CFA) PVIs, and infrapopliteal procedures.

RESULTS

There were 15,892 PVI, 2352 suprainguinal bypass, and 3480 infrainguinal bypass procedures analyzed. Changes consistent with the appropriateness ratings for PVI included more interventions for severe symptoms (72% vs 66.6%; P < .001), improvement in postoperative OMT (83% vs 79.7%; P < .001), fewer patients on dialysis undergoing PVI (2% vs 2.7%; P < .002), and less interventions on complex (TASC II C/D) aortoiliac (6.3% vs 9.5%; P < .001) and femoropopliteal (4.5% vs 5.8%; P < .001) anatomy. No changes were seen in the rates of preoperative smoking and preoperative OMT use, interventions on octogenarians, or in the use of extra-anatomic suprainguinal bypass, infrapopliteal bypass, or prosthetic conduit. Inconsistent with appropriateness ratings were more patients with congestive heart failure (15.1% vs 12.8%; P < .001) undergoing PVIs, and more PVIs for CFA (5.2% vs 3.4%; P < .001) and isolated infrapopliteal disease (5.7% vs 3.5%; P < .001).

CONCLUSIONS

Since the publication of the AUC, there have been improvements with better OMT on discharge, fewer patients with end-stage renal disease undergoing interventions, and less endovascular treatment of complex disease. However, further work is needed to improve preoperative medical optimization in patients with IC undergoing an invasive intervention and decrease the use of endovascular interventions for CFA and infrapopliteal disease, extra-anatomic aortoiliac revascularizations, and prosthetic conduit use.

Long-term outcomes in the smoking claudicant after peripheral vascular interventions

OBJECTIVE

Emphasis on tobacco cessation, given the urgent and emergent nature of vascular surgery, is less prevalent than standard elective cases such as hernia repairs, cosmetic surgery, and bariatric procedures. The goal of this study is to determine the effect of active smoking on claudicating individuals undergoing peripheral vascular interventions (PVIs). Our goal is to determine if a greater emphasis on education should be placed on smoking cessation in nonurgent cases scheduled through clinic visits and not the Emergency Department.

METHODS

This study was performed using the multi-institution de-identified Vascular Quality Initiative/Medicare-linked database (Vascular Implant Surveillance and Interventional Outcomes Network [VISION]). Claudicants who underwent PVI for peripheral arterial occlusive disease between 2004 and 2019 were included in our study. Our final sample consisted of a total of 18,726 patients: 3617 nonsmokers (19.3%) (NSs), 9975 former smokers (53.3%) (FSs), and 5134 current smokers (27.4%) (CSs). We performed propensity score matching on 29 variables (age, gender, race, ethnicity, treatment setting [outpatient or inpatient], obesity, insurance, hypertension, diabetes, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, previous coronary artery bypass graft, carotid endarterectomy, major amputation, inflow treatment, prior bypass or PVI, preoperative medications, level of treatment, concomitant endarterectomy, and treatment type [atherectomy, angioplasty, stent]) between NS vs FS and FS vs CS. Outcomes were long-term (5-year) overall survival (OS), limb salvage (LS), freedom from reintervention (FR), and amputation-free survival (AFS).

RESULTS

Propensity score matching resulted in 3160 well-matched pairs of NS and FS and 3750 well-matched pairs of FS and CS. There was no difference between FS and NS in terms of OS (hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.82-1.09; P = .43), FR (HR, 0.96; 95% CI, 0.89-1.04; P = .35), or AFS (HR, 0.90; 95% CI, 0.79-1.03; P = .12). However, when compared with CS, we found FS to have a higher OS (HR, 1.18; 95% CI, 1.04-1.33; P = .01), less FR (HR, 0.89; 95% CI, 0.83-0.96; P = .003), and greater AFS (HR, 1.16; 95% CI, 1.03-1.31; P = .01).

CONCLUSIONS

This multi-institutional Medicare-linked study looking at elective PVI cases in patients with peripheral artery disease presenting with claudication found that FSs have similar 5-year outcomes in comparison to NSs in terms of OS, FR, and AFS. Additionally, CSs have lower OS and AFS when compared with FSs. Overall, this suggests that smoking claudicants should be highly encouraged and referred to structured smoking cessation programs or even required to stop smoking prior to elective PVI due to the perceived 5-year benefit.